We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves GSK’s Jemperli for Endometrial Cancer
FDA Approves GSK’s Jemperli for Endometrial Cancer
The FDA has granted accelerated approval to GlaxoSmithKline’s monoclonal antibody Jemperli (dostarlimab) for treating women with recurrent or advanced endometrial cancer.